Where do Immunovant, Inc.'s ratios come from?

Every ratio is computed from Immunovant, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.

Immunovant, Inc. IMVT Ratios & Valuation

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	Q4 '26	Q3 '26	Q2 '26	Q1 '26	Q4 '25
Returns
Return on equity	-64.8%-2.4pp	-69.3%+4.8pp	-95.9%-3.8pp	-77.6%-13.0pp	-62.5%-9.5pp
Return on assets	-58.3%-1.0pp	-63%+4.6pp	-84.6%-4.6pp	-71.5%-13.6pp	-57.4%-9.0pp
Liquidity
Current ratio	9.1×-2.1×	15.7×+9.7×	9.1×+1.5×	12.3×-0.8×	11.2×-2.5×
Quick ratio	9.1×-2.1×	15.7×+9.7×	9.1×+1.5×	12.3×-0.8×	11.2×-2.5×
Cash ratio	8.6×-1.7×	15×+9.5×	8.3×+1.2×	11.3×-1.1×	10.4×-2.7×
Leverage
Debt-to-equity	0×0.0×	——	——	——	0×0.0×
Debt-to-assets	0×0.0×	——	——	——	0×0.0×
Interest coverage	-19×-3.3×	-18.1×-4.5×	-18.7×-9.2×	-17.7×-9.0×	-15.7×-6.3×
Per Share
Book value per share	$4.67+0.1%	$5.43+126%	$2.99-2.4%	$3.56-4.5%	$4.67+4.3%
Valuation
Market capitalization	$5.06B+74.2%	$5.12B+40.9%	$2.81B-32.5%	$2.73B-28.7%	$2.9B-37.8%
Enterprise value	$4.15B+89.7%	——	——	——	$2.19B-45.7%
Price / book	5.9×+1.8×	5.2×-5.1×	5.4×-3.9×	4.5×-2.6×	4.1×-3.5×
Free cash flow yield	-8.1%+4.9pp	-8.3%+0.7pp	-15.4%-8.8pp	-15.3%-8.9pp	-13%-8.4pp
Earnings yield	-10%+4.3pp	-9.1%+1.5pp	-16.5%-8.8pp	-16.4%-9.3pp	-14.3%-8.7pp

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do Immunovant, Inc.'s ratios come from?: Every ratio is computed from Immunovant, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.